Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Antisense Therapy against CCR3 and the Common Beta...
Journal article

Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses

Abstract

RATIONALE: The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (beta(c)) of IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptors. OBJECTIVES: This study examined the effects of inhaled TPI ASM8 on sputum cellular influx, CCR3 and beta(c) mRNA and protein levels, and the airway …

Authors

Gauvreau GM; Boulet LP; Cockcroft DW; Baatjes A; Cote J; Deschesnes F; Davis B; Strinich T; Howie K; Duong M

Journal

American Journal of Respiratory and Critical Care Medicine, Vol. 177, No. 9, pp. 952–958

Publisher

American Thoracic Society

Publication Date

May 1, 2008

DOI

10.1164/rccm.200708-1251oc

ISSN

1073-449X